There were no statistically significant differences between doses of 200 U and 300 U or between injections into the detrusor and submucosa .
CONCLUSION BoNT-A is effective and safe in treating NDO after SCI .
There were no statistically significant differences between doses of 200 U and 300 U or between injecting into the detrusor and submucosa .
PURPOSE OnabotulinumtoxinA ( BoNT-A ) is a promising therapy for treating neurogenic detrusor overactivity ( NDO ) in individuals with spinal cord injury ( SCI ) .
This systematic review and meta- analysis aim ed to carry out an in-depth review and to make an objective estimation of the efficacy and safety of BoNT-A on NDO after SCI .
Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder.
AIM To vali date a self-administered instrument , the Medication Adherence Self-Report Inventory ( MASRI ) for measuring adherence to anti-cholinergic medication for overactive bladder ( OAB ) . METHODS Prospect i ve study in 131 women with OAB treated with fesoterodine .  Adherence was measured at 8 and 12 weeks using an interviewer administered brief medication question naire ( BMQ ) that assesses barriers to adherence ( criterion st and ard ) , the MASRI , and pill count . Construct , concurrent and discriminant validity of the MASRI was assessed . We hypothesized that women who were non-adherent as measured by the MASRI would be more likely to have a belief barrier than women who were adherent to medication . RESULTS Women diagnosed as non-adherent by the MASRI were more likely to report a belief barrier to taking medication as compared to adherent women at 8 weeks ( 80 % vs. 38 % , P < 0.001 ) and at 12 weeks ( 70 % vs. 40 % , P = 0.003 ) . Significant correlations were noted between adherence rates measured by the MASRI and the BMQ at 8 weeks ( r = 0.87 , P < 0.001 ) and 12 weeks ( r = 0.90 , P < 0.001 ) . Moderate correlation was noted between the adherence rate as measured by the MASRI and pill count at 8 weeks ( r = 0.49 , P = 0.02 ) but not at 12 weeks ( r = 0.05 , P = 0.87 ) . The MASRI correctly identified 93 % and 96 % of non-adherent women at 8 and 12 weeks , respectively . Sensitivity , specificity , and positive likelihood ratio of the MASRI for predicting non-adherence was 91 % , 82 % , and 5.1 at 8 weeks and 90 % , 85 % and 6.1 at 12 weeks . CONCLUSIONS The MASRI is a valid self-administered tool for measuring adherence to anti-cholinergic medication in women with OAB
There were no statistically significant differences between doses of 200 U and 300 U or between injections into the detrusor and submucosa .
CONCLUSION BoNT-A is effective and safe in treating NDO after SCI .
There were no statistically significant differences between doses of 200 U and 300 U or between injecting into the detrusor and submucosa .
PURPOSE OnabotulinumtoxinA ( BoNT-A ) is a promising therapy for treating neurogenic detrusor overactivity ( NDO ) in individuals with spinal cord injury ( SCI ) .
This systematic review and meta- analysis aim ed to carry out an in-depth review and to make an objective estimation of the efficacy and safety of BoNT-A on NDO after SCI .